Positive News Sentiment NASDAQ:FENC Fennec Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. $6.15 +0.44 (+7.71%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$5.71▼$6.3550-Day Range$5.17▼$6.2652-Week Range$3.20▼$6.55Volume76,937 shsAverage Volume37,808 shsMarket Capitalization$160.26 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Fennec Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside92.9% Upside$12.00 Price TargetShort InterestHealthy1.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.59Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.84 out of 5 starsMedical Sector711th out of 1,428 stocksBiological Products, Except Diagnostic Industry112th out of 218 stocks 3.4 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Fennec Pharmaceuticals has a forecasted upside of 92.9% from its current price of $6.22.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.29% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 18.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 3.1 News and Social Media Coverage News SentimentFennec Pharmaceuticals has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.68% of the stock of Fennec Pharmaceuticals is held by insiders.Percentage Held by Institutions43.62% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow in the coming year, from ($0.45) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFennec Pharmaceuticals has a P/B Ratio of 10.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Fennec Pharmaceuticals (NASDAQ:FENC) StockFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More FENC Stock News HeadlinesJune 10, 2022 | americanbankingnews.comCantor Fitzgerald Weighs in on Fennec Pharmaceuticals Inc's FY2023 Earnings (NASDAQ:FENC)May 12, 2022 | finance.yahoo.comFennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 6, 2022 | finance.yahoo.comInflation crushes market caps of Triangle's biggest public companies – except these onesMay 3, 2022 | finance.yahoo.comCan Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?April 27, 2022 | seekingalpha.comFennec refiling gets FDA review for Pedmark to prevent chemotherapy-induced hearing loss in childrenApril 27, 2022 | finance.yahoo.comFennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™April 5, 2022 | baystreet.caThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TLS, FENC and ASTRMarch 28, 2022 | benzinga.comThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, CRNC and CABAMarch 25, 2022 | bizjournals.comAfter two rejections and no revenue, Fennec again seeks FDA approvalMarch 25, 2022 | finance.yahoo.comFennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth ConferenceMarch 24, 2022 | nasdaq.comFennec Resubmits Pedmark NDA To FDAMarch 24, 2022 | marketwatch.comFennec Pharmaceuticals Files Again for FDA OK of Pedmark >FENCMarch 24, 2022 | seekingalpha.comFennec refiles for FDA approval of Pedmark for preventing ototoxicity due to chemotherapyMarch 11, 2022 | benzinga.comSHAREHOLDER ALERT: EHTH ELMS FENC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action DeadlinesMarch 11, 2022 | benzinga.comThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ELMS, FENC and MPMarch 8, 2022 | benzinga.comThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ELMS, FENC and ERICMarch 8, 2022 | benzinga.comThe Gross Law Firm Announces Class Actions on Behalf of Shareholders of ELMS, TLS and FENCMarch 5, 2022 | benzinga.comROSEN, A TOP RANKED LAW FIRM, Encourages Fennec...March 4, 2022 | benzinga.comCLASS ACTION UPDATE for ELMS, FENC and GATO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersMarch 4, 2022 | apnews.comDEADLINE ALERT for FENC, AFIB, SPWR, and PLSE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMarch 2, 2022 | benzinga.comCLASS ACTION UPDATE for OSH, ELMS and FENC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersMarch 1, 2022 | seekingalpha.comFennec Pharmaceuticals GAAP EPS of -$0.18March 1, 2022 | benzinga.comThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BMBL, FENC and SPWRFebruary 27, 2022 | benzinga.comThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BHG, FENC and GATOFebruary 25, 2022 | benzinga.comSHAREHOLDER ALERT: OSH FENC GATO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action DeadlinesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/05/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+95.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.74% Return on Assets-68.17% Debt Debt-to-Equity Ratio0.36 Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual Sales$170,000.00 Price / Sales942.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book10.08Miscellaneous Outstanding Shares26,059,000Free Float23,536,000Market Cap$160.26 million OptionableOptionable Beta-0.02 Fennec Pharmaceuticals Frequently Asked Questions Should I buy or sell Fennec Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock. View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks. What is Fennec Pharmaceuticals' stock price forecast for 2022? 4 Wall Street research analysts have issued 1-year target prices for Fennec Pharmaceuticals' shares. Their FENC stock forecasts range from $10.00 to $14.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 95.1% from the stock's current price. View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Fennec Pharmaceuticals' stock performed in 2022? Fennec Pharmaceuticals' stock was trading at $4.40 at the start of the year. Since then, FENC stock has increased by 39.8% and is now trading at $6.15. View the best growth stocks for 2022 here. When is Fennec Pharmaceuticals' next earnings date? Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Fennec Pharmaceuticals. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). View Fennec Pharmaceuticals' earnings history. Who are Fennec Pharmaceuticals' key executives? Fennec Pharmaceuticals' management team includes the following people: Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)Mr. Robert C. Andrade, Chief Financial Officer (Age 43)Mr. Mark Gowland, ControllerMr. Lei Fang, Pres of Pharstat IncMs. Anne McKay, Regulatory Consultant (Age 64) Who are some of Fennec Pharmaceuticals' key competitors? Some companies that are related to Fennec Pharmaceuticals include Cullinan Oncology (CGEM), Immatics (IMTX), Ocugen (OCGN), Century Therapeutics (IPSC), Inhibrx (INBX), Vaxart (VXRT), Immunovant (IMVT), Monte Rosa Therapeutics (GLUE), Brickell Biotech (BBI), C4 Therapeutics (CCCC), Aura Biosciences (AURA), ADMA Biologics (ADMA), Kodiak Sciences (KOD), Aerie Pharmaceuticals (AERI) and HilleVax (HLVX). View all of FENC's competitors. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL). What is Fennec Pharmaceuticals' stock symbol? Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC." How do I buy shares of Fennec Pharmaceuticals? Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fennec Pharmaceuticals' stock price today? One share of FENC stock can currently be purchased for approximately $6.15. How much money does Fennec Pharmaceuticals make? Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $160.26 million and generates $170,000.00 in revenue each year. The company earns $-17,350,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. How can I contact Fennec Pharmaceuticals? Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for Fennec Pharmaceuticals is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490. This page (NASDAQ:FENC) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
